ABSTRACT
It is a prospective study based on the pre introduction evaluation of Norplant implants conducted from September 92 to September 93 in the city of Ouagadougou. 197 women were selected for the study. Based on unemployed women with an average age of 31 years old. The average parity was of 5.47% of patients were multiparas. A gain of weight of an average of 2.43 kg was observed. The main side effects observed was cycle disorders and headache. The continuing rate after 12 months was 96.5%. Conclusion from this study is that Norplant Implants are well tolerated and accepted by women.
PIP: According to the 1989 census, Burkina Faso has a fertility rate of 7.1%. In 1992, the rate of contraceptive use was 8.2%. In an effort to expand the selection of contraceptive methods available in the country, the government of Burkina Faso worked with the Population Council to introduce the Norplant subcutaneous implant method of contraception. Norplant is a long-term, reversible, hormonal contraceptive method employing levonorgestrel. A prospective study based upon the preintroduction evaluation of Norplant was conducted from September 1992 to September 1993 in Ouagadougou. 197 women aged 18-47 years were chosen for the study. They were of mean age 31.9 years with 67% aged 30-39 years. Their mean parity was 5 children with the extremes of 1-11 children. 47% were multiparous, and 69% had already ever used a contraceptive method. The women weighed 42-91 kg, of mean weight 60 kg upon Norplant insertion and 62.43 kg 12 months later. Main secondary effects were cycle disorders and cephaly. The continuation rate of Norplant use after 12 months was 96.5%. These data indicate that Norplant is well accepted and tolerated by women in this setting.
